were that the outcomes probabilities were similar for both the clinics and between the xiv cycles. Future costs and effectiveness were discounted 3% to convert to present values. dropped more than 25% of the current cost, the WMTAC would not be a dominant intervention. In conclusion, WMTAC is a more cost effective option than UMC in KLH.
The WMTAC is cost-effective, as it is able to improve the percentage of time within therapeutic range and reduce the frequency of clinics visits and ward admissions.
Maintaining the TTR above the gold standard of 70%, is important to ensure its' effectiveness.
The incidence of Venous Thromboembolism Embolism (VTE) is increasing globally.
The worldwide incidence exceeds 1 per 1000 (Ministry of Health Malaysia, 2003b , Nordstrom et al., 1992 . VTE is a general term used to describe the blockage of a blood vessel by a blood clot. VTE is often a silent disease and the first appearance can be fatal. Diagnosing and treating VTE patients in the United States with anticoagulants costs United States Dollars (USD) 3.2 to 15.5 billion per year (Cundiff, 2004) , whereas in Europe, the total direct costs of all VTE events were estimated at 
Thromboembolism
Thromboembolism (TE) is a major health problem, where it is the third most common cardiovascular disease after myocardial infarction and stroke (Naess et al., 2007 
Venous Thromboembolism (VTE)
VTE is an important cause of death in hospitals. Treatment of VTE and its' related long term morbidities are associated with considerable health service cost. VTE includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). Three major pathophysiologic determinants of VTE are venous stasis, endothelial injury and hypercoagulability. All risk factors for VTE influence at least one of these three mechanisms (Nicolaides et al., 1971 , Kakkar et al., 1969 , Kumar et al., 2010 (Paraskos et al., 1973 , Riedel et al., 1982 , Torbicki et al., 2008 .
Resolution of proximal DVT is slow and less than half have complete lysis after six months of anticoagulation (Holmstrom et al., 1997) . The risk of recurrence upon cessation of anticoagulation is similar following proximal DVT and PE (Douketis et al., 1998 , Heit et al., 2000 . However, the risk of mortality is two to three folds higher with recurrent PE. Society, 1992 , Levine et al., 2002 , Kearon, 2004 , Galioto et al., 2011 . Mechanical prophylaxis is used for patients who are ineligible for pharmacologic therapy but is less efficacious than pharmacologic methods when used alone (Sachdeva et al., 2010 , Agu et al., 1999 , Kearon and O'Donnell, 2010 . Pharmacological prophylaxis includes low molecular weight heparin (LMWH), pentasaccharide sodium (fondaparinux), unfractionated heparin (UFH) and the newer anticoagulants (dabigatran, rivaroxaban, apixaban) (Geerts et al., 2004 , Kahn et al., 2012 . Maintenance treatment of VTE with anticoagulation is recommended, following initial heparinisation or fondaprinux treatment in patients with VTE (Ministry of Health Malaysia, 2013a).
Atrial fibrillation (AF)
Vascular diseases has been found to increase the risk of AF and AF has likewise been shown to be a major risk factor for vascular disease and cardiovascular death. Both VTE and AF share a number of risk factors such as increasing age, obesity, diabetes, heart failure and hypertension (Olesen et al., 2012) . AF is associated with a pro-thrombotic state, intra-atrial stasis, structural heart disease or blood vessel abnormalities and abnormal platelets haemostasis, which predisposes patients to thrombus formation. This condition leads to stroke and thromboembolism. Antithrombotic therapy has proven to be the only method to 6 reduce AF-related mortality (Hylek et al., 2003) . The CHADS2 (Congestive heart failure, hypertension, age = 75 years, diabetes mellitus, stroke) risk stratification scheme is used to assess stroke risk, where oral anticoagulation therapy is initiated if the score is ≥ 2. A meta-analysis showed that adjusted-dose oral anticoagulation therapy lead to a significant 64% risk reduction of stroke and 26% reduction of all-cause mortality in patients with non-valvular AF (Hart et al., 2007) . In addition to the cost for treatment per admission of MYR 9,000 in tertiary Malaysian education hospital, acute major stroke also lead to at least 10 to 15 clinic visits in the first six months for rehabilitation (Aznida et al., 2012) . AF increases the risk of stroke, which is a leading cause of death and disability worldwide. The appropriate use of oral anticoagulation in this moderate to high risk of stroke population, improves health outcomes (Steinberg and Piccini, 2014).
Anticoagulation Therapy -Vitamin K Antagonists
Warfarin 
Monitoring Anticoagulant Intensity
The Prothrombin Test (PT) is the most common test used to monitor VKA therapy. The PT responds to a reduction of three of the four vitamin K dependent pro-coagulant clotting factors that are reduced by warfarin at a rate proportional to their respective half-lives (Quick, 1935 , van den Besselaar, 1991 , Poller, 2004 
Patient selfmanagement
Patient with physician/ pharmacist Selected patients are trained to selfmonitor INR using POCT, interpret the result and making their own dosing decision.
Anticoagulation Management Models
Various 
Anticoagulation Management in Malaysia
The Malaysian health care system consists of tax-funded and government-run 
Problem Statement
In Malaysia, circulatory system diseases accounted for a total of 170, 933 or 7.55 % 
Study Objective
The study aimed to compare the cost and efficiency of the warfarin mediation therapy adherence clinic (WMTAC) with usual medical clinic (UMC) in the management of chronic warfarin (more than six months) therapy patients in an ambulatory care setting in Kuala Lumpur Hospital (KLH). The efficiency is measured in terms of how the clinic converted its' resources into outcomes which is the anticoagulation control.
The specific objectives of the study are: There are specific difficulties in defining, developing, documenting and reproducing complex interventions that are subject to variations (Campbell et al., 2000a) , such as the anticoagulation clinics as it involves various health professionals, their skill mix, dosing algorithm and drug related problems. In order to evaluate health interventions, a review of previous studies which may have provided some empirical evidence for example, an intervention may have been found effective for a closely related condition or in another country with a different organisation of health care would be useful.
Upon review, the information would be used to identify the type of interventions, study design where there is a need to assess the feasibility of the study and parameters 
Effectiveness of vitamin K antagonist
AF is associated with a 1.5 to 1.9 fold higher risk of death, which is part due to strong association between AF and thromboembolic events (Wolf et al., 1991 , Steinberg et al., 2015 . In a meta-analysis, the relative risk reduction with VKA was highly significant and amounted to 64%, corresponding to an absolute annual risk reduction in all strokes of 2.7%. This reduction was similar for both primary and secondary prevention and for both disabling and non-disabling strokes. Many strokes occur when patients were not taking therapy or were sub-therapeutically anticoagulated.
All-cause mortality was significantly reduced (26%) by adjusted-dose VKA versus control (placebo) (Camm et al., 2010) . This is simple to calculate, but biased as it depends on the tendency of the physicians to perform repeated tests soon after an out of range INR (Samsa and Matchar, 2000) .
Though ultimately event rates are the outcomes of interest in comparison to the intermediate outcomes of TTR or the proportions of in-range test, even in high risk populations, significant clinical events are relatively uncommon (Disertori et al., 2013, Samsa and Matchar, 2000) . Sample size using event rates as the primary outcome need a much larger sample size than the sample size for a study using the TTR (Samsa and Matchar, 2000) . Strong relationship between TTR and event rates are not only consistent with the pharmacokinetics of warfarin and consensus statements (Hirsh et al., 1998) , but observed in large number of studies with different patient populations, target ranges and intensity measurement scales (Samsa and Matchar, 2000, Wan et al., 2008) . As clinical outcomes need larger sample sizes and are not easily observed in trials, since it is highly coherent with TTRs, TTR should be used as the primary outcome while recording the clinical events as secondary outcomes (Holbrook et al., 2012) .
In order to achieve maximal protection against stroke and to minimize bleeding complications, warfarin therapy must be tightly controlled and maintained within a narrow therapeutic index of INR values (Melamed et al., 2011) . TTR is a standard quality measure of the use of warfarin (Samsa et al., 2000 , Piccini et al., 2014 . Rosendaal et al., 1993) . This method allows the determination of the optimal effects of anticoagulation (Rosendaal et al., 1993) and takes into account actual days in target range and allows one to calculate INR specific incidence rates of adverse events (Schmitt et al., 2003) . A TTR of more than 60% is a generally accepted threshold above which warfarin confers significant benefit compared with antiplatelet therapy (Connolly et al., 2008) . The association between TTR and clinical outcomes was confirmed in a multi-level multivariable model, whereas in a separate model, a 10% increase in TTR independently predicted a 20% lower rate (p < 0.001) of the composite clinical outcome (e.g. stroke) among patients on warfarin (Van Spall et al., 2012 , Apostolakis et al., 2012 . Occurrence of adverse events, both thromboembolic and haemorrhagic events are used as a secondary outcomes measure (Lalonde et al., 2008) .
Effectiveness of Anticoagulation Management Services (AMS)
Systematic outpatient anticoagulation services are systems of care designed to coordinate and optimize the delivery of anticoagulation therapy by evaluating patient-specific risks and benefits to determine the appropriateness of therapy; Bungard et al., 2009 , Donovan et al., 2006 . However, studies followed -up for less than 6 month had a tendency to observe higher bleeding events and lower thromboembolic events. The study design of future trials were recommended to be 
Cost of Anticoagulation Management Services
Costs are important attributes in economic evaluations, thus appropriate costs and benefits must be considered. To be of maximum value, economic evaluations must be flexible enough to take into account local variations in resource costs and the estimation of cost has to be a comprehensive approach (Haycox and Walley, 1997) .
Cost definitions in the current review were from various currencies of various years.
First, costs expressed in various currencies and base years were converted to USD in year 2010 using the purchasing power parity. Second, all the relevant costs were then converted to International Dollars (Int. $) of the same year. A summary of clinical outcomes and cost of anticoagulation therapy management is shown in Table 2. 2.
An earlier study of the cost of anticoagulation management compared the AMS and UMC in terms of adverse events noted that the savings in terms of prevention of subsequent morbidity was USD 211, 776 per year for all patients receiving warfarin in the AMS (Garabedian-Ruffalo et al., 1985) , whereas another study noted that AMS in comparison to UMC produced a savings of USD 132, 086 annually in expenses for warfarin related hospitalizations and emergency department visits (Chiquette et al., 1998) . Though the costs of AMS are available based on adverse events and consultation cost, little available evidence identifies the details of the costing method (Aziz et al., 2011 , Bjorholt et al., 2007 , Menzin et al., 2005 , Anderson, 2004 , Schulman et al., 2010 Chan Variations in the costing method and the type of resources used were noted in all the studies. Some used actual treatment cost, some used estimates of treatment and adverse event costs and some used only adverse event costs, whereas others used the cost of all the resources used for the clinic (Chan et al., 2006 , Garabedian-Ruffalo et al., 1985 , Chiquette et al., 1998 , Aziz et al., 2011 . A time-motion analysis would be necessary to validate the time estimates in a study (Anderson, 2004) .
